What it is: An investigational weekly dual agonist combining GLP-1 and glucagon receptor activation, with particular research focus on liver fat and energy expenditure.
Research suggests: Phase 2 trials show significant weight loss and liver fat reduction, with notable results in NASH (non-alcoholic steatohepatitis) research populations.
Best for: Metabolic liver disease and obesity researchers
Key thing to know: Not FDA approved; the glucagon receptor component directly targets liver fat accumulation, the primary differentiator from pure GLP-1 agents like semaglutide.
What is Survodutide?
Survodutide (formerly BI 456906) is an investigational dual receptor agonist developed by Boehringer Ingelheim that simultaneously targets GLP-1 receptors and glucagon receptors. This receptor combination places survodutide in a distinct mechanistic category within the growing field of multi-receptor metabolic agents. Where tirzepatide pairs GLP-1 with GIP, survodutide pairs GLP-1 with glucagon, producing a different downstream metabolic profile that has attracted particular interest for its effects on liver fat and energy expenditure.
Survodutide is being studied for two primary indications: obesity and non-alcoholic steatohepatitis (NASH), also called metabolic-associated steatohepatitis (MASH). NASH represents a major unmet medical need, as it can progress to cirrhosis and liver failure and few effective pharmacological treatments have been established. Survodutide's glucagon receptor component produces direct effects on hepatic lipid metabolism that make it a mechanistically compelling candidate for this indication.
It is not FDA approved and remains an investigational compound. Phase 3 trials are ongoing for both obesity and NASH indications as of 2025.
How it works.
GLP-1 receptor agonism reduces appetite by acting on brainstem and hypothalamic circuits, slows gastric emptying, and improves glucose-dependent insulin secretion. These are the same mechanisms shared with semaglutide and tirzepatide, representing survodutide's appetite and glycemic component.
The glucagon receptor agonism component adds a distinct second mechanism. Glucagon is primarily known as a counter-regulatory hormone that raises blood glucose, which raises concern about combining glucagon agonism with a compound intended to improve metabolic health. However, in the context of obesity and liver disease, glucagon receptor activation also produces meaningful metabolic benefits: it increases energy expenditure, promotes fat breakdown (lipolysis), and has direct effects on hepatic lipid metabolism that reduce fat accumulation in the liver.
These hepatic effects are particularly relevant to NASH, where excess liver fat is the defining pathological feature.
Think of GLP-1 as managing appetite and blood sugar while glucagon simultaneously signals the liver to stop accumulating fat and increase fat burning. When both signals are active, the result is greater total fat loss and liver fat reduction than GLP-1 alone can produce. The net effect on blood glucose is neutral or beneficial because the GLP-1 component's insulin-stimulating activity offsets the glucose-raising effect of glucagon in most patients, though this balance requires monitoring in individuals with diabetes.
What the research shows.
Phase 2 trial data for survodutide in obesity showed dose-dependent weight loss of up to 18.7% over 46 weeks, a result competitive with the leading GLP-1 agents currently approved or in late-stage development. The liver fat reduction data was particularly notable: the highest-dose group showed significant decreases in hepatic fat content as measured by MRI-PDFF, a validated quantitative measure of liver fat. In participants with NASH, histological improvements were observed in a meaningful proportion of subjects.
These results establish survodutide as a genuine contender in both obesity and NASH treatment research. The dual indication potential is scientifically significant because obesity and NASH frequently co-occur, and a single agent capable of addressing both would represent a meaningful clinical advance. Phase 3 trials are now enrolling for both indications.
The key limitation is that Phase 3 data is not yet available. Phase 2 trials, while well-designed, involve smaller populations and shorter durations than are required to establish efficacy and safety for regulatory approval. Long-term cardiovascular outcomes, durability of liver histology improvements, and safety in broader populations remain open questions.
Biomarkers to review first.
Research protocols for survodutide reference the following biomarkers as important baseline context. Given its dual effects on metabolic function and liver fat, both metabolic and liver markers are relevant before any protocol consideration.
How it compares to other compounds.
Survodutide is most often discussed in the research literature in comparison to other leading metabolic agents rather than in combination with them. The compounds below are the primary reference points researchers use to contextualise survodutide's efficacy and mechanism.